Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
AYTU vs BMRA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
AYTU Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 9–1 Matrix Metrics)
AYTU Overall Winner
6-Pillar Tally: AYTU 5 – 0 BMRA (1 Tie)
Matrix Metrics: AYTU 9 – 1 BMRA
As of Nov 16, 2026, AYTU BioPharma, Inc. (AYTU) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AYTU carries a Unified Composite Score of 48.9/100 (HOLD) at $1.81 (9.2x Forward P/E, -14.4% operating margin), whereas BMRA carries 44.5/100 (HOLD) at $1.36 (N/M Forward P/E, -125.2% operating margin).
- Technical & Structure Timing Caution: AYTU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7); meanwhile BMRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About AYTU vs BMRA
AYTU
Head-to-Head Winner
AYTU BioPharma, Inc. Common Stock
$1.81
+1.69% 1D
Market Cap
$19.6M
TTM Revenue
$58M
Forward P/E
9.2x
Beta / 30D Vol
0.65β · 35% Vol
Unified Composite Score
48.9
HOLD
Tech 49.0
Fund 53.0
Flow 50.0
Mom 64.0
Weinstein Technical Phase
Markdown · Sell / avoid
BMRA
Biomerica Inc
$1.36
+0.0% 1D
Market Cap
$6.0M
TTM Revenue
$4.3M
Forward P/E
N/M
Beta / 30D Vol
0.67β · 62% Vol
Unified Composite Score
44.5
HOLD
Tech 40.0
Fund 47.0
Flow 50.0
Mom 44.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (AYTU 5 – 0 BMRA)
1. Valuation Multiples
AYTU
Forward P/E
9.2x
N/M
Trailing P/E
9.2x
N/M
PEG Ratio
N/M
N/M
EV / Revenue
0.3x
1.1x
2. Growth & Scale
AYTU
Revenue Growth (YoY)
+6.4%
-8.3%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$58M
$4.3M
Market Cap
$19.6M
$6.0M
3. Profitability & Quality
AYTU
Gross Margin
64.0%
0.9%
Operating Margin
-14.4%
-125.2%
Net Profit Margin
-24.8%
-115.5%
Return on Equity (ROE)
-52.5%
-113.8%
4. Balance Sheet & Cash Flow
AYTU
Cash Generation (TTM)
-$1.4M
-$3.2M
Cash Flow Margin
-2.4%
-73.5%
Net Cash / Leverage
$4.9M Net Cash
$1.1M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
Tie
Options Structure Phase
UNCLASSIFIED
UNCLASSIFIED
Current IV / %ile
N/A (N/A)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
AYTU
OpEx & R&D Intensity
78.4% of Rev ($45M)
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Drug Manufacturers - Specialty & Generic Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: AYTU (9) vs BMRA (1)| Institutional Metric | AYTU | BMRA | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $19.6M | $6.0M | AYTU | |
| Trailing P/E Ratio | 9.2x | N/M | AYTU | |
| Forward P/E Ratio | 9.2x | N/M | AYTU | |
| Revenue Growth (YoY) | +6.4% | -8.3% | AYTU | |
| Operating Margin (TTM) | -14.4% | -125.2% | AYTU | |
| Net Profit Margin | -24.8% | -115.5% | AYTU | |
| Return on Equity (ROE) | -52.5% | -113.8% | AYTU | |
| 52-Week Range Position | 5% ($2–$3) | 5% ($1–$3) | BMRA | |
| Beta / 30D Volatility | 0.65β · 35% Vol | 0.67β · 62% Vol | AYTU | |
| Unified Institutional Score | 48.9 / 100 (HOLD) | 44.5 / 100 (HOLD) | AYTU | |
| Trailing 12M Revenue (USD) | $58M | $4.3M | Scale | |
| Gross Profit Margin (TTM) | 64.0% | 0.9% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 0.3x EV/Rev | N/M PEG · 1.1x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$1.4M ($4.9M Net Cash) | -$3.2M ($1.1M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
AYTU +15.22 pp
3M Horizon
BMRA +8.31 pp
6M Horizon
AYTU +25.75 pp
1Y Horizon
AYTU +33.46 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | AYTU Revenue | BMRA Revenue | AYTU Op. Margin | BMRA Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | $10M | $10M | -230.1% | -46.4% | BMRA |
| FY2020 | $30M | $10M | -76.5% | -41.0% | BMRA |
| FY2021 | $70M | $10M | -89.7% | -104.2% | AYTU |
| FY2022 | $100M | $20M | -113.7% | -24.0% | BMRA |
| FY2023 | $110M | $10M | -15.9% | -135.3% | AYTU |
| FY2024 | $70M | $10M | -2.4% | -117.6% | AYTU |
| FY2025 | $70M | $10M | -11.8% | -96.7% | AYTU |
| FY2026 | $60M | $0M | -14.4% | -119.5% | AYTU |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
AYTU
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact AYTU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
BMRA
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact BMRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
AYTU Moat Profile
Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
OpEx & R&D Reinvestment
78.4% of Rev ($45M)
90D Engineering Disclosures
0 Published
BMRA Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ AYTU vs BMRA Key Questions & Quantitative Answers
As of Nov 16, 2026, AYTU BioPharma, Inc. (AYTU) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AYTU carries a Unified Composite Score of 48.9/100 (HOLD) at $1.81 (9.2x Forward P/E, -14.4% operating margin), whereas BMRA carries 44.5/100 (HOLD) at $1.36 (N/M Forward P/E, -125.2% operating margin). Technical & Structure Timing Caution: AYTU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7); meanwhile BMRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
AYTU leads the Growth & Scale pillar: AYTU posts +6.4% YoY revenue growth and +0.0% YoY earnings growth on $58M TTM revenue (64.0% gross margin, -14.4% operating margin), compared with BMRA at -8.3% YoY revenue growth and +0.0% YoY earnings growth on $4.3M TTM revenue (0.9% gross margin, -125.2% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), AYTU cumulative revenue shifted +500.0% while BMRA shifted +0.0%. In operating R&D and SG&A reinvestment, AYTU deploys 78.4% of Rev ($45M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BMRA.
AYTU screens cheaper on headline valuation multiples. AYTU trades at 9.2x Forward P/E, 9.2x Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-2.4% FCF margin), whereas BMRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-73.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AYTU (-52.5% ROE) versus BMRA (-113.8% ROE) capital efficiency.
In options market volatility and institutional positioning, AYTU carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.65β · 35% Vol realized risk). By comparison, BMRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.67β · 62% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
BMRA vs AYTU · Reverse Pair
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking
VRT vs ETN
· AI Power & Thermal